Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III study of vericiguat in worsening chronic heart failure meets primary endpoint

Nov. 20, 2019

COR-001 suppresses hsCRP in patients with chronic kidney disease

Nov. 20, 2019

DWP-212525, a next-generation therapeutic for autoimmune diseases

Nov. 20, 2019

Celldex begins phase Ia study with KIT inhibitor CDX-0159

Nov. 20, 2019

Haplodeficiency disrupts microglial responses in AD models

Nov. 20, 2019

RQ-00490721 prevents cardiac dysfunction in mouse model of heart failure

Nov. 20, 2019

Seviprotimut-L demonstrates safety and efficacy in part B1 of MAVIS phase III study

Nov. 20, 2019

Novel prostate cancer bone metastasis model in humanized mice

Nov. 20, 2019

Positive data presented for WP-1220 in patients with CTCL

Nov. 20, 2019

Novel potent OXE receptor antagonists with prolonged plasma lifetime for eosinophilic diseases

Nov. 20, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...